Individuals with metabolically healthy overweight/obesity have higher fat utilization than metabolically unhealthy individuals

Nutrients

Volumn 8, Issue 1, 2016, Pages

  Pujia, Arturo ^a   Gazzaruso, Carmine ^b   Ferro, Yvelise ^a   Mazza, Elisa ^a   Maurotti, Samantha ^a   Russo, Cristina ^a   Lazzaro, Veronica ^a   Romeo, Stefano ^a,c   Montalcini, Tiziana ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Clinical Institute Beato Matteo   (Italy)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Diabetes; Fat utilization; Metabolic syndrome; Metabolically unhealthy obesity; Nutrition assessment; Obesity

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; FAT; GLUCOSE BLOOD LEVEL;

ADULT; ANAMNESIS; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MONITORING; CALORIMETRY; CARDIOVASCULAR RISK; CAROTID ARTERY; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIETARY INTAKE; FEMALE; HEMOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; OBESITY; PHENOTYPE; RADIOIMMUNOASSAY; RESPIRATORY QUOTIENT; AGED; BLOOD; BODY MASS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; INDIRECT CALORIMETRY; METABOLICALLY BENIGN OBESITY; METABOLISM; MIDDLE AGED; REFERENCE VALUE; RISK FACTOR;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; CALORIMETRY, INDIRECT; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FATS; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OBESITY, METABOLICALLY BENIGN; OVERWEIGHT; REFERENCE VALUES; RISK FACTORS;

EID: 84953924247     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8010002     Document Type: Article

References (56)

1. Calori, G.; Lattuada, G.; Piemonti, L.; Garancini, M.P.; Ragogna, F.; Villa, M.; Mannino, S.; Crosignani, P.; Bosi, E.; Luzi, L.; et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: The cremona study. Diabetes Care 2011, 34, 210-215. [CrossRef] [PubMed]
2. Kip, K.E.; Marroquin, O.C.; Kelley, D.E.; Johnson, B.D.; Kelsey, S.F.; Shaw, L.J.; Rogers, W.J.; Reis, S.E. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: A report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Circulation 2004, 109, 706-713. [CrossRef] [PubMed]
3. Stefan, N.; Haring, H.U.; Hu, F.B.; Schulze, M.B. Metabolically healthy obesity: Epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013, 1, 152-162. [CrossRef]
4. Meigs, J.B.; Wilson, P.W.F.; Fox, C.S.; Vasan, R.S.; Nathan, D.M.; Sullivan, L.M.; D’Agostino, R.B. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J. Clin. Endocrinol. Metab. 2006, 91, 2906-2912. [CrossRef] [PubMed]
5. Appleton, S.L.; Seaborn, C.J.; Visvanathan, R.; Hill, C.L.; Gill, T.K.; Taylor, A.W.; Adams, R.J. North West Adelaide Health Study Team. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: A cohort study. Diabetes Care 2013, 36, 2388-2394. [CrossRef] [PubMed]
6. DeBoer, M.D. Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: A need for screening tools to target interventions. Nutrition 2013, 29, 379-386. [CrossRef] [PubMed]
7. Arner, P. Regional differences in protein production by human adipose tissue. Biochem. Soc. Trans. 2001, 29, 72-75. [CrossRef] [PubMed]
8. Koves, T.R.; Ussher, J.R.; Noland, R.C.; Slentz, D.; Mosedale, M.; Ilkayeva, O.; Bain, J.; Stevens, R.; Dyck, J.R.; Newgard, C.B.; et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008, 7, 45-56. [CrossRef] [PubMed]
9. Bandyopadhyay, G.K.; Yu, J.G.; Ofrecio, J.; Olefsky, J.M. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 2006, 55, 2277-2285. [CrossRef] [PubMed]
10. Kelley, D.E.; Goodpaster, B.; Wing, R.R.; Simoneau, J.A. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am. J. Physiol. 1999, 277, E1130-E1141. [PubMed]
11. Blaak, E.E. Basic disturbances in skeletal muscle fatty acid metabolism in obesity and type 2 diabetes mellitus. Proc. Nutr. Soc. 2004, 63, 323-330. [CrossRef] [PubMed]
12. Toft-Nielsen, M.B.; Damholt, M.B.; Madsbad, S.; Hilsted, L.M.; Hughes, T.E.; Michelsen, B.K.; Holst, J.J. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2001, 86, 3717-3723. [CrossRef] [PubMed]
13. Vilsbøll, T.; Krarup, T.; Deacon, C.F.; Madsbad, S.; Holst, J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50, 609-613. [CrossRef] [PubMed]
14. De León, D.D.; Crutchlow, M.F.; Ham, J.Y.; Stoffers, D.A. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int. J. Biochem. Cell Biol. 2006, 38, 845-859. [CrossRef] [PubMed]
15. Pannacciulli, N.; Bunt, J.C.; Koska, J.; Bogardus, C.; Krakoff, J. Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am. J. Clin. Nutr. 2006, 84, 556-560. [PubMed]
16. Conarello, S.L.; Li, Z.; Ronan, J.; Roy, R.S.; Zhu, L.; Jiang, G.; Liu, F.; Woods, J.; Zycband, E.; Moller, D.E.; et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 2003, 100, 6825-6830. [CrossRef] [PubMed]
17. McNeill, G.; Bruce, A.C.; Ralph, A.; James, W.P. Inter-individual differences in fasting nutrient oxidation and the influence of diet composition. Int. J. Obes. 1988, 12, 455-463. [PubMed]
18. Schutz, Y. Abnormalities of fuel utilization as predisposing to the development of obesity in humans. Obes. Res. 1995, 3 (Suppl. 2), S173-S178. [CrossRef]
19. Schutz, Y.; Flatt, J.P.; Jéquier, E. Failure of dietary fat intake to promote fat oxidation: A factor favoring the development of obesity. Am. J. Clin. Nutr. 1989, 50, 307-314. [PubMed]
20. Zurlo, F.; Lillioja, S.; Esposito-Del Puente, A.; Nyomba, B.L.; Raz, I.; Saad, M.F.; Swinburn, B.A.; Knowler, W.C.; Bogardus, C.; Ravussin, E. Low ratio of fat to carbohydrate oxidation as predictor of weight gain: Study of 24-h RQ. Am. J. Physiol. 1990, 259, E650-E657. [PubMed]
21. Ferro, Y.; Gazzaruso, C.; Coppola, A.; Romeo, S.; Migliaccio, V.; Giustina, A.; Pujia, A.; Montalcini, T. Fat utilization and arterial hypertension in overweight/obese subjects. J. Transl. Med. 2013, 11, 159. [CrossRef] [PubMed]
22. Lorenz, M.W.; Markus, H.S.; Bots, M.L.; Rosvall, M.; Sitzer, M. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation 2007, 115, 459-467. [CrossRef] [PubMed]
23. Di Bello, V.; Carerj, S.; Perticone, F.; Benedetto, F.; Palombo, C.; Talini, E.; Giannini, D.; la Carrubba, S.; Antonini-Canterin, F.; di Salvo, G.; et al. Carotid intima-media thickness in asymptomatic patients with arterial hypertension without clinical cardiovascular disease: Relation with left ventricular geometry and mass and coexisting risk factors. Angiology 2009, 60, 705-713. [CrossRef] [PubMed]
24. Montalcini, T.; Gazzaruso, C.; Ferro, Y.; Migliaccio, V.; Rotundo, S.; Castagna, A.; Pujia, A. Metabolic fuel utilization and subclinical atherosclerosis in overweight/obese subjects. Endocrine 2013, 44, 380-385. [CrossRef] [PubMed]
25. Montalcini, T.; Lamprinoudi, T.; Morrone, A.; Mazza, E.; Gazzaruso, C.; Romeo, S.; Pujia, A. Nutrients utilization in obese individuals with and without hypertriglyceridemia. Nutrients 2014, 21, 790-798. [CrossRef] [PubMed]
26. Montalcini, T.; Lamprinoudi, T.; Gorgone, G.; Ferro, Y.; Romeo, S.; Pujia, A. Subclinical cardiovascular damage and fat utilization in overweight/obese individuals receiving the same dietary and pharmacological interventions. Nutrients 2014, 6, 5560-5571. [CrossRef] [PubMed]
27. Centers for Disease Control and Prevention. Tobacco use among adults—United States. MMWR 2006, 55, 1145-1148.
28. Psaty, B.M.; Furberg, C.D.; Kuller, L.H.; Bild, D.E.; Rautaharju, P.M.; Polak, J.F.; Bovill, E.; Gottdiener, J.S. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: The cardiovascular health study. Arch. Intern. Med. 1999, 59, 1339-1347. [CrossRef]
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285, 2486-2497.
30. Montalcini, T.; Gorgone, G.; Fava, A.; Romeo, S.; Gazzaruso, C.; Pujia, A. Carotid and brachial arterial enlargement in postmenopausal women with hypertension. Menopause 2012, 9, 145-149. [CrossRef] [PubMed]
31. Montalcini, T.; Gorgone, G.; Garzaniti, A.; Gazzaruso, C.; Pujia, A. Artery remodelling and abdominal adiposity in nonobese postmenopausal women. Eur. J. Clin. Nutr. 2010, 64, 1022-1024. [CrossRef] [PubMed]
32. Talluri, T.; Lietdke, R.J.; Evangelisti, A.; Talluri, J.; Maggia, G. Fat-free mass qualitative assessment with bioelectric impedance analysis (BIA). Ann. N. Y. Acad. Sci. 1999, 873, 94-98. [CrossRef] [PubMed]
33. Zemel, M.B.; Bruckbauer, A. Effects of a leucine and pyridoxine-containing nutraceutical on fat oxidation, and oxidative and inflammatory stress in overweight and obese subjects. Nutrients 2012, 4, 529-541. [CrossRef] [PubMed]
34. Mazumder, P.K.; O’Neill, B.T.; Roberts, M.W.; Buchanan, J.; Yun, U.J.; Cooksey, R.C.; Boudina, S.; Abel, E.D. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004, 53, 2366-2374. [CrossRef] [PubMed]
35. Young, M.E.; Guthrie, P.H.; Razeghi, P.; Leighton, B.; Abbasi, S.; Patil, S.; Youker, K.A.; Taegtmeyer, H. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 2002, 51, 2587-2595. [CrossRef] [PubMed]
36. Choi, C.S.; Savage, D.B.; Abu-Elheiga, L.; Liu, Z.X.; Kim, S.; Kulkarni, A.; Distefano, A.; Hwang, Y.J.; Reznick, R.M.; Codella, R.; et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc. Natl. Acad. Sci. USA 2007, 104, 16480-16485. [CrossRef] [PubMed]
37. Turner, N.; Bruce, C.R.; Beale, S.M.; Hoehn, K.L.; So, T.; Rolph, M.S.; Cooney, G.J. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: Evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes 2007, 56, 2085-2092. [CrossRef] [PubMed]
38. Aasum, E.; Belke, D.D.; Severson, D.L.; Riemersma, R.A.; Cooper, M.; Andreassen, M.; Larsen, T.S. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am. J. Physiol. Heart Circ. Physiol. 2002, 283, H949-H957. [CrossRef] [PubMed]
39. Belke, D.D.; Larsen, T.S.; Gibbs, E.M.; Severson, D.L. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am. J. Physiol. Endocrinol. Metab. 2000, 279, E1104-E1113. [PubMed]
40. An, J.; Muoio, D.M.; Shiota, M.; Fujimoto, Y.; Cline, G.W.; Shulman, G.I.; Koves, T.R.; Stevens, R.; Millington, D.; Newgard, C.B. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat. Med. 2004, 10, 268-274. [CrossRef] [PubMed]
41. Yechoor, V.K.; Patti, M.E.; Saccone, R.; Kahn, C.R. Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. Proc. Natl. Acad. Sci. USA 2002, 99, 10587-10592. [CrossRef] [PubMed]
42. Roden, M. Muscle triglycerides and mitochondrial function: Possible mechanisms for the development of type 2 diabetes. Int. J. Obes. (Lond.) 2005, 2 (Suppl. 2), S111-S115. [CrossRef]
43. Ma, Z.A.; Zhao, Z.; Turk, J. Mitochondrial dysfunction and β-cell failure in type 2 diabetes mellitus. Exp. Diabetes Res. 2012, 2012. [CrossRef] [PubMed]
44. Robitaille, J.; Houde, A.; Lemieux, S.; Pérusse, L.; Gaudet, D. Variants within the muscle and liver isoforms of the carnitine palmitoyltransferase I (CPT1) gene interact with fat intake to modulate indices of obesity in French-Canadians. J. Mol. Med. 2007, 85, 129-137. [PubMed]
45. Wolfgang, M.J.; Kurama, T.; Dai, Y.; Suwa, A.; Asaumi, M.; Matsumoto, S.I.; Cha, S.H.; Shimokawa, T.; Lane, M.D. The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proc. Natl. Acad. Sci. USA 2006, 103, 7282-7287. [PubMed]
46. Kim, T.; Moore, J.F.; Sharer, J.D.; Yang, K.; Wood, P.A.; Yang, Q. Carnitine Palmitoyltransferase 1b Deficient Mice Develop Severe Insulin Resistance after Prolonged High Fat Diet Feeding. J. Diabetes Metab. 2014, 5, 1000401. [CrossRef] [PubMed]
47. Bergman, M. Inadequacies of current approaches to prediabetes and diabetes prevention. Endocrine 2013, 44, 623-633. [PubMed]
48. Den Besten, G.; Bleeker, A.; Gerding, A.; van Eunen, K.; Havinga, R.; van Dijk, T.H.; Oosterveer, M.H.; Jonker, J.W.; Groen, A.K.; Reijngoud, D.J.; et al. Short-Chain Fatty Acids Protect against High-Fat Diet-Induced Obesity via a PPARγ-Dependent Switch from Lipogenesis to Fat Oxidation. Diabetes 2015, 64, 2398-2408. [CrossRef] [PubMed]
49. Hinnouho, G.M.; Czernichow, S.; Dugravot, A.; Batty, G.D.; Kivimaki, M.; Singh-Manoux, A. Metabolically healthy obesity and risk of mortality: Does the definition of metabolic health matter? Diabetes Care 2013, 36, 2294-2300. [PubMed]
50. Rey-López, J.P.; de Rezende, L.F.; Pastor-Valero, M.; Tess, B.H. The prevalence of metabolically healthy obesity: A systematic review and critical evaluation of the definitions used. Obes. Rev. 2014, 15, 781-790. [CrossRef] [PubMed]
51. Phillips, C.M. Metabolically healthy obesity: Definitions, determinants and clinical implications. Rev. Endocr. Metab. Disord. 2013, 14, 219-227. [PubMed]
52. Blüher, M. Are there still healthy obese patients? Curr. Opin. Endocrinol. Diabetes Obes. 2012, 19, 341-346. [CrossRef] [PubMed]
53. Katzmarzyk, P.T.; Church, T.S.; Janssen, I.; Ross, R.; Blair, S.N. Metabolic syndrome, obesity, and mortality: Impact of cardiorespiratory fitness. Diabetes Care 2005, 28, 391-397. [CrossRef] [PubMed]
54. Voulgari, C.; Tentolouris, N.; Dilaveris, P.; Tousoulis, D.; Katsilambros, N.; Stefanadis, C. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J. Am. Coll. Cardiol. 2011, 58, 1343-1350. [CrossRef] [PubMed]
55. Song, Y.; Manson, J.E.; Meigs, J.B.; Ridker, P.M.; Buring, J.E.; Liu, S. Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women. Am. J. Cardiol. 2007, 100, 1654-1658. [CrossRef] [PubMed]
56. Di Sarra, D.; Tosi, F.; Bonin, C.; Fiers, T.; Kaufman, J.M.; Signori, C.; Zambotti, F.; Dall’Alda, M.; Caruso, B.; Zanolin, M.E.; et al. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism. J. Clin. Endocrinol. Metab. 2013, 98, 2581-2588. [CrossRef] [PubMed]